A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs RO 5545965 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Roche
- 06 Jun 2017 Status changed from active, no longer recruiting to completed.
- 23 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.